Genitourinary Cancer Science Highlights
This session highlights six of the most clinically relevant abstracts within the Genitourinary Cancer track of the 2022 ASTRO Annual Meeting Scientific Program. These noteworthy scientific abstracts share important findings and feature cutting edge research from leaders in the field. The Discussant compares and contrasts the current data to help you digest the latest science; places the study into context; and describes how the study can be put into clinical practice, if recommended.
Highlighted Abstracts include –
- Conventional vs Hypofractionated, Radiotherapy for High-risk Prostate Cancer: 7-year Outcomes of the Randomized, Non-inferiority, Phase 3 PCS5 Trial
- A Randomized Phase III Trial Comparing Health-related Quality of Life after Low Dose Rate (LDR) or High Dose Rate (HDR) Prostate Brachytherapy Boost Combined with External Beam Pelvic Radiotherapy (EBRT)
- Magnetic Resonance Imaging-guided vs. Computed Tomography-guided Stereotactic Body Radiotherapy for Prostate Cancer (MIRAGE): Primary Endpoint Analysis Phase III Randomized Trial
- Patient Reported Quality of Life after Moderately Hypofractionated Proton Beam Therapy or Intensity Modulated Radiation Therapy for Prostate Cancer
- The Influence of Pelvic Lymph Node Dissection Volumes on Clinical Outcomes in NRG/RTOG 0534
- Multi-institutional Matched Comparison of Radical Cystectomy to Trimodality Therapy for Muscle Invasive Bladder Cancer (MIBC)
This activity is available from May 23, 2023, through 11:59 p.m. Eastern time on December 31, 2023.
This activity was originally recorded at ASTRO’s 2022 Annual Meeting.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, physicists and radiation dosimetrists.
Upon completion of this activity, participants:
- Assess selected randomized and comparative trials in prostate and bladder cancer
- Compare and contrast current data in Genitourinary Cancer
Discussant: Gerard Morton, MD, Sunnybrook-Odette Cancer Centre, University of Toronto
- No conflicts of interest to disclose
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 0.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 0.50 Certificate of AttendanceThis activity was designated for 0.50 AMA PRA Category 1 Credit™.
ASTRO members must log in to the ASTRO website to view and receive the free member rate.
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website until December 31, 2023, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.